NCT00514137View on ClinicalTrials.gov

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

August 31, 2010

Conditions
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

sunitinib malate

Oral 37.5 mg each day of the 6-week cycle (continuous dosing).

Trial Locations (1)

55905

Mayo Clinic Cancer Research Consortium, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00514137 - Sunitinib in Treating Patients With Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter